ENGINEERED ENONE REDUCTASE AND KETOREDUCTASE VARIANT ENZYMES
The present disclosure provides engineered enone reductase enzymes (EREDs), polypeptides having ERED activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing ERED enzymes are also provided. The present disclosure also provides engineered ketoreductase enzymes (KREDs), polypeptides having KRED activity, and polynucleotides encoding these enzymes, as well as vectors and host cells comprising these polynucleotides and polypeptides. Methods for producing KRED enzymes are also provided. The present disclosure further provides compositions comprising the ERED and KRED enzymes and methods of using the engineered ERED and KRED enzymes. The present disclosure finds particular use in the production of pharmaceutical compounds.
1 . An engineered enone reductase comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NOs: 262, 10, 20, 162, 282, 294, 322, and/or 346, or a functional fragment thereof, wherein the polypeptide sequence of said engineered enone reductase comprises at least one substitution or substitution set and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NOs: 262, 10, 20, 162, 282, 294, 322, and/or 346.
2 . The engineered enone reductase of claim 1 , wherein said polypeptide sequence has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 10, and wherein the polypeptide sequence of said enone reductase comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 32/127/250/261/297/384, 5, 10, 13, 18/103, 19/260/363/394, 30, 32/127/250/384, 44, 56, 92, 99, 100, 103, 103/154, 107, 109, 124, 149, 154, 156, 168, 169, 172, 183, 209, 250, 250/290/384, 250/309/384, 250/384, 279, 306, 307, 341, 359, 369, 394, 398, and 399, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 10.
3 . The engineered enone reductase of claim 1 , wherein said polypeptide sequence of said engineered enone reductase has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 20, and wherein said polypeptide sequence of said engineered enone reductase comprises at least one substitution or substitution set at one or more positions selected from 32/44/103/107/124/127/150/250, 32/44/103/107/124/127/341/394, 32/44/107/124/127/150/183, 32/103/107/124, 32/103/107/124/127/150/250, 32/103/107/124/183/250, 32/103/107/124/209/250, 32/103/107/124/250/394, 32/103/109/154/168/183/341/398, 32/107/124/209/394, 32/124/127/250, 32/183, 32/183/341/399, 38, 40, 44/103/107/124/127, 44/103/107/124/127/183, 44/103/124/127/150/183/260, 44/103/124/250/394, 83, 103/107/124, 103/107/124/127/150, 103/107/124/209/394, 103/107/124/250, 114, 118, 124/150, 148, and 261, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 20.
4 . The engineered enone reductase of claim 1 , wherein said polypeptide sequence of said engineered enone reductase has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 162, and wherein said polypeptide sequence of said engineered enone reductase comprises at least one substitution or substitution set at one or more positions selected from 4, 7, 7/307, 56/378, 95, 100, 109, 127, 146/333, 161, 209, 209/378, 258, 297, 298, 299, 302, 306, 307, 333, 336, 341, 359, and 378, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 162.
5 . The engineered enone reductase of claim 1 , wherein said polypeptide sequence of said engineered enone reductase has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 262, and wherein said polypeptide sequence of said engineered enone reductase comprises at least one substitution or substitution set at one or more positions selected from 4/100/209/258/359/378, 4/151/307/378, 4/151/333, 4/151/359/378, 4/209/359, 4/209/359/378, 7/95/100, 95/100/326/333/378, 95/100/326/378, 95/258/378, 95/333, 100/146/151/258/359/378, 100/209/258/359, 100/378, 146/151/359/378, 209, 209/258, 209/298/359/378, 209/333/359, 258/378, 341, and 378, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 262.
6 . The engineered enone reductase of claim 1 , wherein said polypeptide sequence of said engineered enone reductase has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 282, and wherein said polypeptide sequence of said engineered enone reductase comprises at least one substitution or substitution set at one or more positions selected from 89, 243, and 283, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 282.
7 . The engineered enone reductase of claim 1 , wherein said polypeptide sequence of said engineered enone reductase has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 294, and wherein said polypeptide sequence of said engineered enone reductase comprises at least one substitution or substitution set at one or more positions selected from 47, 118, 148, 258/261, 314, 374/378, 377/378, and 378, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 294.
8 . The engineered enone reductase of claim 1 , wherein said polypeptide sequence of said engineered enone reductase has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 322, and wherein said polypeptide sequence of said engineered enone reductase comprises at least one substitution or substitution set at one or more positions selected from 47/89/95/148/258/261, 47/89/95/243/258/261/378, 47/89/258, 47/95, 89/95/243, 95/148, 95/148/243/258/261, 95/148/243/261, 95/148/258/261, 95/243, 100/243, 100/243/374, and 148/243, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 322.
9 . The engineered enone reductase of claim 1 , wherein said polypeptide sequence of said engineered enone reductase has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 346, and wherein said polypeptide sequence of said engineered enone reductase comprises at least one substitution or substitution set at one or more positions selected from 10, 11, 13, 20, 21, 29, 64, 99, 99/398, 108, 175, 235, 243, 320, 333, 388, 392, 393, and 397, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 346.
10 . An engineered ketoreductase comprising a polypeptide sequence having at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NOs: 432 and/or 476, or a functional fragment thereof, wherein the polypeptide sequence of said engineered ketoreductase comprises at least one substitution or substitution set and wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NOs: 432 and/or 476.
11 . The engineered ketoreductase of claim 10 , wherein said polypeptide sequence of said engineered ketoreductase has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 432, and wherein the polypeptide sequence of said ketoreductase comprises at least one substitution or substitution set at one or more positions in said polypeptide sequence selected from 21/103, 2/72, 2/72/172, 21, 21/65/72/73/103, 21/65/72/131/147/181, 21/65/72/147, 21/65/103/152, 21/65/131/152, 21/65/147/152, 21/65/152, 21/72/73/103, 21/72/103, 21/72/103/131/152/226, 21/72/103/147, 21/72/103/147/152/181, 21/72/131/181/197, 21/72/152/181, 21/73/103, 21/73/131/147, 21/73/147, 21/73/181, 21/103, 21/103/147, 21/103/147/152, 21/147, and 26/173/221, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 432.
12 . The engineered ketoreductase of claim 10 , wherein said polypeptide sequence of said engineered ketoreductase has at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NO: 476, and wherein said polypeptide sequence of said engineered ketoreductase comprises at least one substitution or substitution set at one or more positions selected from 17, 43, 45, 54, 71, 96, 190, 194, 195, 198, 205, and 250, wherein the amino acid positions of said polypeptide sequence are numbered with reference to SEQ ID NO: 476.
13 . The engineered enone reductase of claim 1 , wherein said engineered enone reductase comprises a variant engineered enone reductase set forth in SEQ ID NOs: 10, 20, 162, 262, 282, 294, 322, and/or 346.
14 . The engineered ketoreductase of claim 10 , wherein said engineered ketoreductase comprises a variant engineered ketoreductase set forth in SEQ ID NOs: 432, and/or 476.
15 . The engineered enone reductase of claim 1 , wherein said engineered enone reductase comprises a polypeptide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the sequence of at least one engineered enone reductase variant set forth in the even numbered sequences of SEQ ID NOs: 12-430.
16 . The engineered ketoreductase of claim 10 , wherein said engineered ketoreductase comprises a polypeptide sequence that is at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, 99% or more identical to the sequence of at least one engineered ketoreductase variant set forth in the even numbered sequences of SEQ ID NOs: 434-524.
17 . The engineered enone reductase of claim 1 , wherein said engineered enone reductase comprises a polypeptide sequence set forth in at least one of the even numbered sequences of SEQ ID NOs: 12-430.
18 . The engineered ketoreductase of claim 10 , wherein said engineered ketoreductase comprises a polypeptide sequence set forth in at least one of the even numbered sequences of SEQ ID NOs: 434-524.
19 . The engineered enone reductase of claim 1 , wherein said engineered enone reductase comprises at least one improved property compared to a wild-type enone reductase or another engineered enone reductase.
20 . The engineered ketoreductase of claim 10 , wherein said engineered ketoreductase comprises at least one improved property compared to a wild-type ketoreductase or another engineered ketoreductase.
21 . The engineered enone reductase of claim 19 , wherein said improved property comprises improved activity on a substrate.
22 . The engineered ketoreductase of claim 20 , wherein said improved property comprises improved activity on a substrate.
23 . The engineered enone reductase of claim 21 , wherein said substrate comprises compound (1).
24 . The engineered ketoreductase of claim 22 , wherein said substrate comprises compound (2).
25 . The engineered enone reductase of claim 1 , wherein said engineered enone reductase is purified.
26 . The engineered ketoreductase of claim 10 , wherein said engineered ketoreductase is purified.
27 . A polynucleotide sequence encoding at least one engineered enone reductase of claim 1 .
28 . A polynucleotide sequence encoding at least one engineered enone reductase comprising at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NOs: 9, 19, 161, 261, 281, 293, 321, and/or 345, or a functional fragment thereof.
29 . The polynucleotide sequence of claim 27 , wherein said polynucleotide sequence is operably linked to a control sequence.
30 . The polynucleotide sequence of claim 27 , wherein said polynucleotide sequence is codon optimized.
31 . The polynucleotide sequence of claim 27 , wherein said polynucleotide sequence comprises a polynucleotide sequence set forth in the odd numbered sequences of SEQ ID NOs: 11-429.
32 . An expression vector comprising at least one polynucleotide sequence of claim 27 .
33 . A host cell comprising at least one polynucleotide sequence of claim 27 .
34 . A method of producing an engineered enone reductase in a host cell, comprising culturing the host cell of claim 33 , under suitable conditions, such that at least one engineered enone reductase is produced.
35 . A polynucleotide sequence encoding at least one engineered ketoreductase of claim 10 .
36 . A polynucleotide sequence encoding at least one engineered ketoreductase comprising at least 85%, 86%, 87%, 88%, 89%, 90%, 91%, 92%, 93%, 94%, 95%, 96%, 97%, 98%, or 99% sequence identity to SEQ ID NOs: 432 and/or 476, or a functional fragment thereof.
37 . The polynucleotide sequence of claim 35 , wherein said polynucleotide sequence is operably linked to a control sequence.
38 . The polynucleotide sequence of claim 35 , wherein said polynucleotide sequence is codon optimized.
39 . The polynucleotide sequence of claim 35 , wherein said polynucleotide sequence comprises a polynucleotide sequence set forth in the odd numbered sequences of SEQ ID NOs: 433-523.
40 . An expression vector comprising at least one polynucleotide sequence of claim 35 .
41 . A host cell comprising at least one polynucleotide sequence of claim 35 .
42 . A method of producing an engineered ketoreductase in a host cell, comprising culturing the host cell of claim 41 , under suitable conditions, such that at least one engineered ketoreductase is produced.